Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 26;218(5):1706–1724. doi: 10.1083/jcb.201807165

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Goel et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — Homeostatic potentiation can be balanced with both depression and AZ scaling. (A) Schematic and representative traces of recordings from wild type, endo, and rab3 mutants combined with vGlut overexpression (rab3+vGlut-OE: w;OK6-Gal4,rab3^rup/rab3^rup,UAS-vGlut) before and after PhTx application. Diminished mEPSP amplitudes are observed following PhTx application, while EPSP amplitudes are maintained at baseline levels due to a homeostatic increase in presynaptic neurotransmitter release (quantal content). (B and C) Quantification of EPSP amplitude (B) and mEPSP and quantal content values (C) after PhTx application normalized as a percentage of baseline values (no PhTx treatment) in the indicated genotypes (n ≥ 6; t test; Table S1). (D and E) Representative live images of muscle 6 NMJ boutons expressing endogenously tagged BRP-GFP (w;BRP-GFP; D) and vGlut-GFP (w;vGlut-GFP; E) at baseline and following 10-min incubation in PhTx. (F–H) Quantification of BRP and vGlut sum intensity of the same puncta before and following PhTx application (F), with an increased average (G) and rightward distribution (H) observed. n ≥ 135, BRP; n ≥ 72, vGlut; ratio paired t test (F), Student’s t test (G), K-S test (H); Table S1. (I) Representative images of boutons immunostained with anti-BRP, anti-vGlut, and anti-HRP in the indicated genotypes before and following PhTx application. A parallel increase in BRP and vGlut intensity is observed in all genotypes following PhTx application. (J) Quantification of sum fluorescence intensity of BRP and vGlut puncta reveals a significant increase in each genotype following PhTx application compared with baseline (no PhTx). (K) Quantification of total fluorescence intensity of BRP and vGlut puncta per NMJ, showing an enhanced total abundance following PhTx application. Error bars indicate ± SEM (n ≥ 6; t test; Table S1). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.